RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Accelerated assessment (European Union), Promising Innovative Medicine (United Kingdom), Paediatric investigation plan (United Kingdom), Priority Review (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC21H28F3N6O6P

InChIKeyXXEDEGOAYSGNPS-ZOWNYOTGSA-N

CAS Registry1354691-97-6

Clinical Trials associated with Leniolisib phosphate

NCT06897358

/ RecruitingPhase 2

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)

In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.

Start Date12 Feb 2025

Sponsor / Collaborator

Pharming Technologies BV

[+1]

NCT06549114

/ RecruitingPhase 2

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.

Start Date21 Oct 2024

Sponsor / Collaborator

Pharming Technologies BV

CTIS2023-508880-61-00

/ Not yet recruitingPhase 1

A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 70 mg film coated tablet in healthy volunteers - LE 1102

Start Date06 Mar 2024

Sponsor / Collaborator

Pharming Technologies BV

100 Clinical Results associated with Leniolisib phosphate

100 Translational Medicine associated with Leniolisib phosphate

100 Patents (Medical) associated with Leniolisib phosphate

Literatures (Medical) associated with Leniolisib phosphate

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era

Article

Author: Pignata, Claudio ; Marzollo, Antonio ; Lodi, Lorenzo ; Ricci, Silvia ; Marinoni, Maddalena ; Trizzino, Antonino ; Barzaghi, Federica ; Lougaris, Vassilios ; Moratti, Mattia ; Martire, Baldassarre ; Milito, Cinzia ; Tommasini, Alberto ; Costagliola, Giorgio ; Montin, Davide ; Badolato, Raffaele ; Zecca, Marco ; Chinello, Matteo ; Giardino, Giuliana ; De Rosa, Antonio ; Panza, Giuseppina ; Baselli, Lucia Augusta ; Rivalta, Beatrice ; Conti, Francesca ; Cancrini, Caterina

BACKGROUND:

Activated Phosphoinositide 3-Kinase (PI3K) δ Syndrome (APDS), an inborn error of immunity due to upregulation of the PI3K pathway, leads to recurrent infections and immune dysregulation (lymphoproliferation and autoimmunity).

METHODS:

Clinical and genetic data of 28 APDS patients from 25 unrelated families were collected from fifteen Italian centers.

RESULTS:

Patients were genetically confirmed with APDS-1 (n = 20) or APDS-2 (n = 8), with pathogenic mutations in the PIK3CD or PIK3R1 genes. The median age at diagnosis was 15.5 years, with a median follow-up of 74 months (range 6-384). The main presenting symptoms were respiratory tract infections alone (57%) or associated with lymphoproliferation (17%). Later, non-clonal lymphoproliferation was the leading clinical sign (86%), followed by respiratory infections (79%) and gastrointestinal complications (43%). Malignant lymphoproliferative disorders, all EBV-encoding RNA (EBER)-positive at the histological analysis, occurred in 14% of patients aged 17-19 years, highlighting the role of EBV in lymphomagenesis in this disorder. Diffuse large B-cell lymphoma was the most frequent. Immunological work-up revealed combined T/B cell abnormalities in most patients. Treatment strategies included immunosuppression and PI3K/Akt/mTOR inhibitor therapy. Rapamycin, employed in 36% of patients, showed efficacy in controlling lymphoproliferation, while selective PI3Kδ inhibitor leniolisib, administered in 32% of patients, was beneficial on both infections and immune dysregulation. Additionally, three patients underwent successful HSCT due to recurrent infections despite ongoing prophylaxis or lymphoproliferation poorly responsive to Rapamycin.

CONCLUSIONS:

This study underscores the clinical heterogeneity and challenging diagnosis of APDS, highlighting the importance of multidisciplinary management tailored to individual needs and further supporting leniolisib efficacy.

01 Apr 2025·PEDIATRIC BLOOD & CANCER

Towards Targeted Therapies in Childhood Autoimmune Cytopenias: A Report on Leniolisib Use

Letter

Author: Alimi, Aurélia ; Leverger, Guy ; Maitre, Julie ; Perdereau, Stéphane ; Semeraro, Michaela ; Picard, Capucine ; Héritier, Sebastien ; Hadjadj, Jérôme ; Laucat, Frédéric Rieux

21 Jan 2025·CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study

Article

Author: Nagamuthu, Chenthila ; Chandra, Anita ; Liu, Sichen ; Seidel, Markus G ; Tutein Nolthenius, Joanne ; Ehl, Stephan ; Kracker, Sven ; Whalen, John ; Maccari, Maria Elena ; Gulas, Ioana ; Dron, Louis ; Velummailum, Russanthy

Abstract:

Leniolisib, an oral, targeted phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, was well-tolerated and efficacious versus placebo in treating individuals with activated PI3Kδ syndrome (APDS), an ultra-rare inborn error of immunity (IEI), in a 12-week randomised controlled trial. However, longer-term comparative data versus standard of care are lacking. This externally controlled study compared the long-term effects of leniolisib on annual rate of respiratory tract infections and change in serum immunoglobulin M (IgM) levels versus current standard of care, using data from the leniolisib single-arm open-label extension study 2201E1 (NCT02859727) and the European Society for Immunodeficiencies (ESID) registry. The endpoints were chosen following feasibility assessment considering comparability and availability of data from both sources. Baseline characteristics between groups were balanced through inverse probability of treatment weighting. The leniolisib-treated group included 37 participants, with 62 and 49 participants in the control group for the respiratory tract infections and serum IgM analyses, respectively. Significant reductions in the annual rate of respiratory tract infections (rate ratio: 0.34; 95% confidence interval [CI]: 0.19, 0.59) and serum IgM levels (treatment effect: –1.09 g/L; 95% CI: –1.78, –0.39, P = 0.002) were observed in leniolisib-treated individuals versus standard of care. The results were consistent across all sensitivity analyses, regardless of censoring, baseline infection rate definition, missing data handling, or covariate selection. These novel data provide an extended comparison of leniolisib treatment versus standard of care, highlighting the potential for leniolisib to deliver long-term benefits by restoring immune system function and reducing infection rate, potentially reducing complications and treatment burden.

News (Medical) associated with Leniolisib phosphate

20 Mar 2025

·endpts.com

Two-thirds of recent rare disease drugs relied on just one trial, plus confirmatory evidence, FDA team finds

New research published by FDA authors found that 67% of non-oncologic rare disease marketing applications approved between 2020 and 2023 used only one clinical trial plus confirmatory evidence to demonstrate effectiveness. The law defines “substantial evidence of effectiveness” as data from two or more adequate and well-controlled clinical trials. But many rare diseases have small patient populations, making multiple trials unethical or impossible to conduct, in addition to “a lack of drug development tools, such as established clinical outcome measures,” several members of the FDA’s rare diseases team and others from FDA’s Office of Clinical Pharmacology wrote in an article published in Clinical Pharmacology & Therapeutics on Thursday . The authors said they used FDA databases to identify 60 new non-oncologic rare disease drug and biologic applications with orphan drug designation from 2020 to 2023. They found that 40 out of 60 (67%) applications used one trial plus confirmatory evidence to meet the FDA’s statutory requirement for demonstrating substantial evidence of effectiveness. Meanwhile, 20% of the applications (12 of 60) used just one “highly persuasive” adequate, well-controlled trial, and 13% (8 of 60) used two or more trials. By contrast, the FDA authors noted that 71% (49 of 69) of non-oncologic, new molecular entity applications indicated for the treatment of common diseases and approved within the same time frame used two or more trials. The changing dynamic for approving rare disease drugs is notable, especially since from 2020 through 2023, more than half of all novel drug approvals were for rare diseases, the paper notes. The authors cite several examples “to highlight the successful use of mechanistic, pharmacodynamic, and other types of CE,” including the 2023 approval of Pharming’s leniolisib for an immunodeficiency disease known as activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome, or APDS, and Sanofi’s 2022 approval for its enzyme replacement therapy Xenpozyme (olipudase alfa). The authors note the most common types of confirmatory evidence (CE) used by rare disease drug developers were: “The importance of prospectively considering the role CE may play in rare disease drug development cannot be understated,” the FDA authors wrote. “Both the quality and quantity of CE are important considerations. As noted previously, beginning at the early stages of drug development, sponsors should outline their plan for developing CE and engage with the FDA to seek guidance on demonstrating SEE [substantial evidence of effectiveness].”

Drug ApprovalOrphan DrugImmunotherapy

20 Mar 2025

·www.globenewswire.com

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation. The Phase II clinical trial is a single arm, open-label, dose range-finding, multi-center study to be conducted in approximately 20 patients 12 years of age and older. The trial will include patients with a CVID diagnosis, a requirement for evidence of lymphoproliferation, and at least one additional clinical manifestation of immune dysregulation, including interstitial lung disease, autoimmune cytopenias, or enteropathy. The objectives for the trial are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and explore clinical efficacy of leniolisib in the targeted CVID with immune dysregulation population. The trial has been designed to inform a subsequent Phase III program. The lead investigator for the Phase II study is Jocelyn Farmer, M.D./PhD, Director of the Clinical Immunodeficiency Program of Beth Israel Lahey Health (Lahey Hospital & Medical Center in Burlington, MA), with additional clinical sites in the US, UK and EU. Jocelyn Farmer, MD, PhD; Allergist and Immunologist, Lahey Hospital & Medical Center, Burlington, MA; Director, Clinical Immunodeficiency Program, Beth Israel Lahey Health, MA; Associate Professor, UMass Chan-Lahey Medical School, Burlington, MA commented:“As a physician with clinical responsibility for a large group of common variable immunodeficiency (CVID) patients, I understand the significant disease burden they face. This includes autoimmune and end-organ lympho-infiltrative clinical complications resulting from their immune dysregulation. Due to the absence of effective therapies for these CVID patients, the disease manifestations can easily progress, leading to the well-documented early mortality in this patient group. PI3Kẟ is a multi-faceted regulator of lymphocytes, functioning to control their proliferation, differentiation, antibody production and migration, and hence leniolisib has significant potential to treat the immune dysregulation seen in these CVID patients. Therefore, I am very excited that we have dosed our first patient with leniolisib in this phase 2 proof of concept study in CVID patients with immune dysregulation, where leniolisib provides an opportunity to help these patients with a large, unmet medical need.” CVID represents the largest group of symptomatic primary immunodeficiency (PID) patients, where approximately 50% display autoimmune, lymphoproliferative and/or end-organ lympho-infiltrative clinical manifestations driven by immune dysregulation.1,2,3 CVID patients with immune dysregulation have an unmet medical need with an 11-fold enhanced rate of mortality as compared to CVID patients with infectious manifestations alone, and the majority exhibit a spectrum of clinical manifestations with similarities to activated phosphoinositide 3-kinase delta syndrome (APDS) patients.1,4 Based on available epidemiological data, it is estimated that the global prevalence of the targeted CVID with immune dysregulation population is approximately 39 patients per million. Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:“The initiation of this second Phase II clinical study outside the APDS indication is a substantial expansion of our work in primary immunodeficiency disorders. Unlike the initial APDS indication and our ongoing Phase II study in PIDs with immune dysregulation with specific genetic drivers, CVID patients are diagnosed based on standard clinical findings, independently of genetics. CVID patients with immune dysregulation have significant clinical unmet need, with no approved therapies, and represent a significantly larger patient population. We are therefore very excited about the potential leniolisib holds for treating CVID patients with immune dysregulation and look forward to enrolling more patients over the coming months.” Leniolisib is marketed under the brand name Joenja® in the U.S. for the treatment of APDS in adult and pediatric patients 12 years of age and older. About leniolisibLeniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved in the U.S. and several other countries as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and interim open label extension data has supported the safety and tolerability of long-term leniolisib administration.5,6 Leniolisib is currently under regulatory review in the European Economic Area, Canada and Australia for APDS, with plans to pursue further regulatory approvals in Japan and South Korea. Leniolisib is also being evaluated in two Phase III clinical trials in children with APDS, and in a Phase II clinical trial in primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn. Forward-Looking Statements   This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. References Resnick ES, et al. Blood. 2012 119(7): 1650-1657.Boileau J, et al. J Autoimmun. 2011 36(1): 25-32. Ramirez NJ, et al. Curr Opin Immunol. 2021 72: 176-185. Farmer JR, et al. Front Immunol. 2018;8: 1740.Rao VK, et al. Blood. 2023;141(9): 971-983.Rao VK, et al. J Allergy Clin Immunol. 2024;153: 265-74. For further public information, contact:Pharming Group, Leiden, the NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E: investor@pharming.com FTI Consulting, London, UKSimon Conway/Alex Shaw/Amy ByrneT: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nl US PRChristina SkrivanT: +1 (636) 352-7883E: Christina.Skrivan@precisionaq.com Attachment Pharming announces start Phase II trial of leniolisib for CVID_EN_20MAR25

Phase 2ImmunotherapyClinical ResultPhase 3Drug Approval

20 Mar 2025

·www.pharming.com

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming Group N.V. announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation. Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million The Phase II clinical trial is a single arm, open-label, dose range-finding, multi-center study to be conducted in approximately 20 patients 12 years of age and older. The trial will include patients with a CVID diagnosis, a requirement for evidence of lymphoproliferation, and at least one additional clinical manifestation of immune dysregulation, including interstitial lung disease, autoimmune cytopenias, or enteropathy. The objectives for the trial are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and explore clinical efficacy of leniolisib in the targeted CVID with immune dysregulation population. The trial has been designed to inform a subsequent Phase III program. The lead investigator for the Phase II study is Jocelyn Farmer, M.D./PhD, Director of the Clinical Immunodeficiency Program of Beth Israel Lahey Health (Lahey Hospital & Medical Center in Burlington, MA), with additional clinical sites in the US, UK and EU.

Phase 2Immunotherapy

100 Deals associated with Leniolisib phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D11158 D11159	-	-	DB16217

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Activated PI3K-delta Syndrome	United States	Pharming Technologies BV	24 Mar 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphadenopathy	Phase 3	United States	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Belarus	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Czechia	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Germany	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Ireland	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Italy	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Netherlands	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	Russia	Novartis Pharmaceuticals Corp.	24 Aug 2015
Lymphadenopathy	Phase 3	United Kingdom	Novartis Pharmaceuticals Corp.	24 Aug 2015
Common Variable Immunodeficiency	Phase 2	United States	Pharming Technologies BV	12 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02859727 (Pubmed) Manual	Phase 3	Activated PI3K-delta Syndrome PI3K Mutation	6	Leniolisib	ruexavqxgl(kupnfbxygm) = Of 83 adverse events through year 5, 90.36% were grade 1; none were grade 4-5 nor deemed leniolisib-related ccrzguaool (umyhgksdbi )	Positive	09 Apr 2024
NCT02435173 (FDA) Manual	Phase 2/3	Activated PI3K-delta Syndrome PI3Kδ mutation	31	JOENJA 70 mg	jzbseblgls(rbapstcaqt) = hearonartp ddzecvasil (unxwczmqhn, 5.34) View more	Positive	24 Mar 2023
				Placebo	jzbseblgls(rbapstcaqt) = vpukahvkjr ddzecvasil (unxwczmqhn, 6.66) View more
NCT02435173 (Pubmed)	Phase 3	Activated PI3K-delta Syndrome	31	Leniolisib 70-mg	geqlbxrgus(tushatakpx) = Fewer patients receiving leniolisib reported study treatment-related adverse events (mostly grades 1-2) compared to those receiving placebo (23.8% vs 30.0%) taxltunukm (yfcoqfvamq )	Positive	18 Nov 2022
NCT02859727 (ASH 12022 \| ASH 22022) Manual	Phase 2/3	Activated PI3K-delta Syndrome	37	Leniolisib	gygrfnmvky(mtxtomnmmn) = qbonttlije teziobkynq (xicumheifz ) View more	Positive	15 Nov 2022
NCT02435173 (EHA2022)	Phase 3	Activated PI3K-delta Syndrome	31	Leniolisib	yxtlliyffd(ayznpnjver) = exfncktwbw mbgdgccpkz (owjgortybs )	-	02 Jun 2022
NCT02435173 (PRNewswire) Manual	Phase 2/3	Activated PI3K-delta Syndrome	-	Leniolisib	fmvcebbxem(vqqrqdowcg) = qhmaxeromt lqvbvacwdg (ookgfekghf ) View more	Positive	01 Apr 2022
				Placebo	fmvcebbxem(vqqrqdowcg) = ftxmagwtav lqvbvacwdg (ookgfekghf ) View more
NCT02435173 (CTgov)	Phase 2/3	Activated PI3K-delta Syndrome \| Lymphadenopathy	37	CDZ173 (Part I: CDZ173)	zpggjwudps(oxajslnozr) = zmlawqretn tglaiblbcn (uvsidbibgz, 1.10) View more	-	11 Mar 2022
				CDZ173 (Part II: CDZ173)	ievwruggky(auzvboibwq) = tcjrxzpeeo jnzdfibrcp (xfgriaqiyc, 0.04) View more
NCT02775916 (CTgov)	Phase 2	Primary Sjögren's syndrome	30	CDZ173 (CDZ173)	nyshbteasl = iomzvgzumm rxanbecogm (jvjuxhtbpa, oucnortlan - vkogebutrq) View more	-	18 Oct 2019
				Placebo (Placebo)	nyshbteasl = pkdlfdltvp rxanbecogm (jvjuxhtbpa, qidjcmtkvs - iuuaqlynfn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis